Synthetic biology has historically relied on bacteria as a testing ground for engineering cell behavior through genetic signals. But a small group of researchers have their sights set on redesigning mammalian cells, which have more complex genetic machinery. Daniel Grushkin meets the scientists aiming to reprogram our bodies' cells for a new generation of tailor-made treatments.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Chen, Y.Y. et al. Proc. Natl. Acad. Sci. USA 107, 8531–8536 (2010).
Danino, T. et al. Nature 463, 326–330 (2010).
Warren, L. et al. Cell Stem Cell 7, 618–630 (2010).
Gardner, T.S. et al. Nature 403, 339–342 (2000).
Kramer, B.P. et al. Nat. Biotechnol. 22, 867–870 (2004).
Ausländer S. et al. Nature 487, 123–127 (2012).
Xie, Z. et al. Science 333, 1307–1311 (2011).
Kemmer, C. et al. Nat. Biotechnol. 28, 355–360 (2010).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Grushkin, D. The new drug circuit. Nat Med 18, 1452–1454 (2012). https://doi.org/10.1038/nm1012-1452
Published:
Issue Date:
DOI: https://doi.org/10.1038/nm1012-1452
This article is cited by
-
Engineering advanced cancer therapies with synthetic biology
Nature Reviews Cancer (2019)
-
Biomedically relevant circuit‐design strategies in mammalian synthetic biology
Molecular Systems Biology (2013)